Tirzepatide versus Semaglutide Once Weekly in Type 2 Diabetes

N Engl J Med. 2022 Feb 17;386(7):e17. doi: 10.1056/NEJMc2114590.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Diabetes Mellitus, Type 2* / drug therapy
  • Gastric Inhibitory Polypeptide
  • Glucagon-Like Peptides / adverse effects
  • Humans

Substances

  • semaglutide
  • Gastric Inhibitory Polypeptide
  • Glucagon-Like Peptides
  • tirzepatide